# Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

> **NCT00636870** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 220 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** Fexofenadine

## Key facts

- **NCT ID:** NCT00636870
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2004-01
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2011-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636870, "Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00636870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*